{
    "nctId": "NCT00752310",
    "officialTitle": "A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects Receiving DRV Combined With RTV Low Dose to Compare the Oral Bioavailability of DRV Suspension to That of DRV 300 mg Tablet Under Fasted and Fed Conditions, and to Assess Multiple Dose Pharmacokinetics of the DRV Suspension",
    "inclusionCriteria": "* Non-smoking, or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection\n* Normal weight as defined by a Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included\n* Able to comply with protocol requirements. Healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, electrocardiogram (ECG), vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis carried out at screening.\n* Must have minimum age of 18 Years\n* Must have maximum age of 55 Years",
    "exclusionCriteria": "* No positive HIV 1 or HIV 2 test at screening\n* no history of significant skin disease such as, but not limited to rash or eruptions, drug allergies, food allergy, dermatitis, eczema, psoriasis, or urticaria\n* no history of allergy to drugs such as, but not limited to, sulphonamides and penicillins\n* no previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication administered in this trial\n* no female subject of childbearing potential without use of effective nonhormonal birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period\n* no positive pregnancy test or breast feeding at screening"
}